Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
Elias Jabbour(The University of Texas MD Anderson Cancer Center), H. Kantarjian(The University of Texas MD Anderson Cancer Center), Vivian G. Oehler(University of Washington), Hengbang Wang, Jörge E. Cortes(The University of Texas MD Anderson Cancer Center), Svetlana Samarina(Kirov Research Institute of Hematology and Blood Transfusion FMBA), Anthony M. Hunter(Emory University), Yifan Zhai(Ascepion Pharmaceuticals (China)), Omer Jamy(University of Alabama at Birmingham), Lixin Jiang(Chinese Academy of Medical Sciences & Peking Union Medical College), Vera Zherebtsova(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Huanshan Guo, Anna Turkina, Cunlin Wang, Olga Uspenskaya(Leningrad Regional Cancer Center), Paul Koller(City of Hope), Vasily Shuvaev(Medical Radiological Research Center), И. Л. Давыдкин(Samara State Medical University), Elza Lomaia(Federal Almazov North-West Medical Research Centre), Dajun Yang(Sun Yat-sen University), Zi Chen(Dartmouth College), Sudipto Mukherjee(Cleveland Clinic), Maria R. Baer(University of Maryland, Baltimore), Tommy Fu
Cited by 26
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
The primary health-care system in China
|The Lancet|2017|1.1k
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2005|951
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
|New England Journal of Medicine|2011|753